Replies to post #8752 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

You could tell by the way the closing date was sliding that problems had surfaced. GE should have gone for the deal because within a couple of years, RECAF will be their best selling test.

[was Gyro]

GS, I was going to let this go since Abbott was supposed to be history, but since that has changed and you mentioned it again, I figure we can talk about it.

You say they mentioned RECAF in the abstract for the July 24th conference - I think I'm missing it or am too dense to infer it. Part of the abstract is posted in message http://www.investorshub.com/boards/read_msg.asp?message_id=20915413

From the speaker bio:
...In the Cancer Core R&D group, Dr. Hemken has worked on the team that developed tissue inhibitor of metalloproteinase-1 (TIMP-1) for the ARCHITECT immunoassay system and on the RECAF project.
You inferred that the RECAF project was complete, however I can't make that leap. It says Dr. Hemken worked on it, but since people get moved around projects frequently, the fact that he is no longer working on it doesn't necessarily indicate that the project is complete.

We are back to parsing language again, so I thought I'd offer a different interpretation. Of course, the 24th may still hold surprises, which would be nice.